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Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disordermarked by the loss ofmotor neurons (MNs) in the brain
and spinal cord, leading to fatally debilitating weakness. Because this disease predominantly affects MNs, we aimed to characterize the
distinct expression profile of that cell type to elucidate underlying disease mechanisms and to identify novel targets that inform onMN
health during ALS disease time course. microRNAs (miRNAs) are short, noncoding RNAs that can shape the expression profile of a cell
and thus often exhibit cell-type-enriched expression. To determine MN-enriched miRNA expression, we used Cre recombinase-
dependent miRNA tagging and affinity purification in mice. By defining the in vivomiRNA expression of MNs, all neurons, astrocytes,
and microglia, we then focused on MN-enriched miRNAs via a comparative analysis and found that they may functionally distinguish
MNs postnatally from other spinal neurons. Characterizing the levels of theMN-enrichedmiRNAs in CSF harvested fromALSmodels of
MN disease demonstrated that one miRNA (miR-218) tracked with MN loss and was responsive to an ALS therapy in rodent models.
Therefore,wehaveused cellular expressionprofiling tools todefine thedistinctmiRNAexpressionofMNs,which is likely to enrich future
studies of MN disease. This approach enabled the development of a novel, drug-responsive marker of MN disease in ALS rodents.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neuro-
degenerative disease in which motor neurons (MNs) are selec-
tively lost. This progressive loss of MNs results in muscle
denervation and atrophy, leading to death within 3–5 years of
symptom onset (Pasinelli and Brown, 2006; Rothstein, 2009).
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Significance Statement
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease inwhichmotor neurons (MNs) in the brain and spinal cord are
selectively lost. To develop tools to aid in our understanding of the distinct expression profiles ofMNs and, ultimately, tomonitor
MNdisease progression, we identified small regulatorymicroRNAs (miRNAs) that were highly enriched or exclusive inMNs. The
signal for one of theseMN-enrichedmiRNAs is detectable in spinal tap biofluid from an ALS ratmodel, where its levels change as
disease progresses, suggesting that it may be a clinically useful marker of disease status. Furthermore, rats treated with ALS
therapy have restored expression of thisMNRNAmarker,making it anMN-specific anddrug-responsivemarker forALS rodents.
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The majority of ALS cases are sporadic, whereas the remaining
10% are familial. Mutations in superoxide dismutase 1 (SOD1)
were the first identified genetic cause of ALS and are responsible
for 20% of familial ALS. Currently, mice and rats containing
mutated human SOD1 (hSOD1) are themost widely usedmodels
and recapitulate the disease pathology faithfully.
MicroRNAs (miRNAs) are small, regulatory RNAs that regulate
the translation of protein-coding RNAs. miRNAs direct transla-
tional repression by partial binding to the 3 UTR of mRNAs after
first being incorporated into an RNA-induced silencing complex
containing Argonaute-2 (Ago2) (Gregory et al., 2005; Chekulaeva
and Filipowicz, 2009;Ha andKim, 2014). Because only partial com-
plementarity is required for miRNA–mRNA interactions, a single
miRNAcanpotentially regulate hundreds ofmRNAs (Selbach et al.,
2008). Emerging data demonstrate thatmiRNAs are powerful regu-
lators of physiological and pathological cellular processes (Ardekani
andNaeini, 2010;O’Connell et al., 2010;SayedandAbdellatif, 2011).
Therefore, miRNA expression is often dysregulated in disease and
miRNAs have been used as both therapeutic and diagnostic targets
(Chen et al., 2008; Koval et al., 2013).
Work from our lab and others found that miR-155, a glial-
enrichedmiRNA, isupregulated in the spinal cordsof end-stageALS
model (SOD1G93A) mice and human autopsy (Koval et al., 2013;
Butovsky et al., 2015). Inhibiting miR-155 significantly delays dis-
ease progression in SOD1G93A mice (Koval et al., 2013; Butovsky et
al., 2015). Despite enthusiasm for this glial miRNA therapeutic ap-
proach, we hypothesized that MN miRNA changes in ALS may be
equally or more important because MN loss and pathology define
the onset of disease andultimately death (Boille´e et al., 2006; Ilieva et
al., 2009). However, because MNs represent only 4% of the mouse
spinal cord volume (Zetterstro¨m et al., 2011), probing miRNA
changes inMNs is challenging andmust be done using a compar-
ative strategy so that the expression profiles of MNs can be dis-
criminated from other CNS cell types. Finally, because ALS is an
adult-onset neurodegenerative disease, we sought to profile
miRNA expression in adult mice.
To assess miRNA expression in CNS cell types, we used a bio-
chemical purification system, miRNA tagging and affinity purifica-
tion (miRAP) (He et al., 2012), inwhich taggedAgo2 is expressed in
particular cell types under the control of the Cre–Lox system. Be-
cause catalytically functional miRNAs must be loaded into the
miRNA-processing protein Ago2 (Hammond et al., 2001; Ham-
mond, 2005), affinity purification via antibodies against Ago2 serves
to isolate active miRNAs from tissue lysates (Chi et al., 2009). Fur-
thermore, by expressing a GFP-myc-tagged version of Ago2 only in
particular cell types, miRNAs from distinct cell populations may be
isolated viamyc orGFP immunoprecipitation (IP) (He et al., 2012).
To determine enriched miRNA expression in CNS cell types, we
crossed miRAP reporter mice [lox-stop-lox-GFP-myc-Ago2 (LSL-
tAgo2)] to mice expressing Cre recombinase under promoters tar-
geting all neurons, MNs, astrocytes, and myeloid cells including
microglia. We discriminated MN-enriched miRNAs from other
CNS cell types via a comparative analysis. The MN-enrichment of
one of these miRNAs (miR-218) has been established previously in
developing MNs and was found to be important for MN function
(Amin et al., 2015; Thiebes et al., 2015).Here,we confirmed theMN
enrichment of miR-218 in adultMNs and demonstrated that it and
otherMNmiRNAsmay play a functional role in defining postnatal
MN identity distinct from other spinal neurons. We predict these
MN-enriched miRNA expression profiles will broadly inform on
MNbiology and studies of diseases specific toMNs. As a first test of
how MN-enriched miRNAs inform on MN disease, we examined




All animal protocols were approved by the Institutional Animal Care and
Use Committee of Washington University at St. Louis and adhered to
National Institutes of Health (NIH) guidelines. All mice were bred on a
congenic C57BL/6J background. To generate cell-specific GFP-myc-
Ago2-expressing mice, a homozygous (ROSA)26Sortm1(CAG-GFP/EiF2c2)Zjh
(LSL-tAgo2) mouse (RRID:IMSR_JAX:017626) was bred to one of four
Cre lines: Synapsin 1 (Syn)-Cre (RRID:IMSR_JAX:003966), choline
acetyltransferase (ChAT)-Cre (RRID:IMSR_JAX:006410), glial fibrillary
acidic protein (GFAP)-Cre (Bajenaru et al., 2002) (a gift from David H.
Gutmann), or lysozyme 2 (Lyz2, LysM)-Cre (RRID:IMSR_JAX:004781).
To visualize the cell types marked by GFAP and Lyz2, we used LSL-
tdTomato mice (RRID:IMSR_JAX:007905). Mice used in experiments
were heterozygous for LSL-tAgo2 and for a cell-specific Cre driver,
whereas control mice were only positive for LSL-tAgo2. C57BL/6J
SOD1G93Amice were originally purchased fromThe Jackson Laboratory
(ID: 004435). For CSF studies, Sprague Dawley nontransgenic, hSOD1
WT (provided by Pak Chan, Stanford University) and the SOD1G93A
(Taconic model 2148) rat lines were used.
At 9 weeks of age, mice were anesthetized with an overdose of inhaled
isoflurane before being perfused with 20–30 ml of cold 1 PBS. Perfu-
sion was critical for the elimination of Lyz2-labeled monocytes in the
blood. Whole spinal cords and whole brainstems (pons and medulla)
were isolated, flash frozen in liquid nitrogen, and stored at80°C.
Histology
Double-label cell type expression. Free-floating 50 m sections from 4%
paraformaldehyde (PFA) fixed brain and spinal cord tissue from either
male or female mice were used for immunohistochemistry. Goat-anti-
ChAT (1:200, Millipore AB144; RRID:AB_11212843) and chicken-anti-
GFP (1:250, Aves, GFP-1020; RRID:AB_10000240) were applied to the
tissues overnight at 4°C.
In situ hybridization. 20 m sections from ChAT-RpL10a-GFP (a gift
from Joseph D. Dougherty) mice were fixed in 4% PFA and acetylated.
No proteinase k digestion was performed. 5, 3-DIG-labeled anti-miR-
218 probes (Exiqon) were hybridized at 49°C overnight. Cy5 Tyramide
Signal Amplification (1:50, PerkinElmer, NEL705A001KT) was per-
formed. Chicken anti-GFP antibody (1:1000, Aves Laboratory, GFP-
1020; RRID:AB_10000240) was used to recognize ChAT-L10a-GFP
MNs. Secondary antibodies were applied to the tissue for 1 h. All sections
were stained with DAPI. Slides were mounted and coverslipped with
Fluoromount (Southern Biotech, 0100-01). Images were acquired with a
Nikon A1Rsi confocal microscope. For formatting, ImageJ (RRID:
SCR_003070) and Adobe Photoshop CS6 Extended were used.
miR-218 fluorescence signal quantification. In situ hybridization slides
were observed using aNikonA1Rsi confocalmicroscope. All imageswere
taken at a 20magnification with the same laser power and pinhole size
and the detector was set so that no saturation occurred. To determine
miR-218 fluorescence signal, three background measurements with no
ChAT-L10a-GFP staining were measured. Each MN was outlined ac-
cording to ChAT-L10a-GFP staining and the fluorescence signal of miR-
218 was measured using ImageJ as described previously (McCloy et al.,
2014). Image analyses were conducted by a blinded reviewer.
SMI-32 motor neuron counts. Free-floating 40 m sections from 4%
PFA fixed lumbar spinal cord tissue from either male or female rats were
used for immunohistochemistry. Mouse-anti-SMI-32 (1:500, BioLeg-
end, SMI-32; RRID:AB_2315331) was applied to the tissues overnight at
4°C. Images were acquired with a Nikon A1Rsi confocal microscope at
20magnification. MN counts were limited to the anterior horn of the
lumbar spinal cord. The number of MNs for each rat is an average of at
least six sections per rat where both sides of the anterior horns were
analyzed. The counting was performed by a blinded reviewer.
miRAP
Brainstem and spinal cords from saline perfused, 63-d-oldmice (3males
and 3 females/line) were harvested, flash frozen in liquid nitrogen, and
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stored at80°C. Tissue was homogenized andmiRAP was conducted as
described previously (He et al., 2012). A BCA assay was performed on all
tissue homogenates to normalize input to the lowest protein concentra-
tion.Next, 700l ofQIAzol (Qiagen)was added directly to the beads and
stored at 20°C. miRAP was performed identically in LSL-tAgo2,
ChAT-Cre, SOD1G93A mice using spinal cord tissue harvested at 70 d
(presymptomatic) and 140 d (symptomatic).
miRNA extraction and quantification
RNA was isolated using miRNeasy kits per manufacturer’s instructions
(Qiagen). miRNA microarrays were performed with preamplification
using low-density rodent MiRNA AB cards set 3.0 (Life Technologies)
on a 7900HT qPCR machine for 40 cycles. Arrays were performed on
tissue from 3malemice/line.MicroarraymiRNA targets were confirmed
with individual TaqMan miRNA qPCR assays (Life Technologies) in
technical duplicates on an Applied Biosystems 7500 Fast Real-Time PCR
System. Cell-type-enriched miRNAs were confirmed with individual as-
says using tissue from three male and three female mice per line.
CSF collection and miRNA extraction and quantification
CSF was obtained from both male and female rats anesthetized with 5%
isoflurane via puncture of cisternamagna and centrifuged at 1000 g for
10min at4°C before freezing supernatant at80°C. The same volume
of CSF is used to extract miRNA with the miRcury RNA Isolation Kit
Biofluids (Exiqon). MS2 carrier RNA (1 g of RNA/100 l of CSF) was
added to CSF to maximize miRNA recovery (Andreasen et al., 2010).
RT-qPCR was performed using the miRCURY LNA Universal RT and
ExiLENT SYBR green kit (Exiqon). Data were analyzed using the 2ddCT
method andmiR-103a-3p, miR-191, andmiR-24 were used as a normal-
ization control (per the manufacturer’s recommendation).
SOD1 antisense oligonucleotide (ASO) treatment
SOD1G93A rats at 65 d of age were anesthetized with 5% isoflurane and
given a 30 l intrathecal bolus injection of 1000 g of ASO (hSOD1:
TTAATGTTTATCAGGAT; scrambled: CCTATAGGACTATCCAGGAA)
or artificial CSF (aCSF) (Tocris Bioscience) between L4 and L5 of the
lumbar spinal cord. Cohorts were gender and litter matched; both male
and female rats were used. CSF and spinal cordwere harvested at 115 d of
age. All surgeries and downstream analyses were done by personnel
blinded to treatment groups.
Hindlimb grip strength
Grip strength was assessed weekly using a grip strength meter (DFIS-2
series digital force gauge; Columbus Instruments). The grip strength of
each rat wasmeasured five times consecutively and the average of the five
readings was recorded as the grip strength. Assessors were blinded to
treatment groups.
Primary Hb9-GFP MN cultures
Primary Hb9-GFP MN cultures were obtained as described previously
(Wang and Marquardt, 2012). Briefly, the ventral spinal cord was dis-
sected from male and female Hb9-GFP E12.5 embryos. The ventral
column was digested using papain (Worthington) and MNs were disso-
ciated and strained through a 40 m strainer. MNs were isolated using a
density gradient of 3% and 9% optiprep (Sigma-Aldrich) and centrifu-
gation. A total of 100,000 cells were plated on poly-ornithine- (Sigma-
Aldrich) and laminin (Sigma-Aldrich)-coated 24-well plates.
miR-218 release and lactate dehydrogenase (LDH) assay
A total of 100,000Hb9-GFPMNswere plated and subsequently treatedwith
1mMsodiumarsenite (Fluka) for 4h.Next, 200l ofmediumwasharvested
at 0, 2, and 4 h and centrifuged at 1000 rpm for 5 min to pellet cells. Then,
175l ofmediumwas removed, leaving thepelletundisturbed, and125l of
mediumwasmixedwith 5 volumes ofQIAzol andRNAwas extracted using
themiRNeasykit (Qiagen).Finally, 50l ofmediumwasused forLDHassay
(Roche). For induced pluripotent stem cell (iPSC)-derived MN cultures,
cells were treated with puromycin (1g/ml) for 72 h.
Fibroblast collection and reprogramming
Fibroblasts were grown in Glutamax (Invitrogen) supplemented with
10% serum. iPSC lines were created and initially characterized with an
NIH-sponsored commercial agreement with iPierian as described previ-
ously (Donnelly et al., 2013).
Human iPSC-derived MN-enriched cultures
iPSCs were maintained in E8 (Thermo Fisher Scientific) and passaged
once every 5–6 d using dispase (Stemcell Technologies). Partially differ-
entiated colonies were removedmanually before each passage and before
starting the differentiation process. iPSCs were differentiated to neuro-
progenitor cells and then toMNs as described previously (Boulting et al.,
2011). To enrich the population of neurons, compound E (Santa Cruz
Biotechnology) and AraC (20 M; Sigma-Aldrich) was added to iPSC
cultures after day 30 to reduce the number of dividing cells (mostly glial
cell populations). After 45 d of differentiation, the cells began to exhibit
more mature neuron and MN phenotypes. Cells were then replated at
day 45 and AraC (20M) was added the following day. This resulted in
a relatively pure population of neurons expressing MN markers.
Human tissues and cells
Autopsy tissues were obtained from patients who consented to partici-
pate in Washington University’s autopsy program (ALS patients) or
consented to tissue donation through the National Disease Research In-
terchange program (non-ALS). Cervical spinal cord autopsy tissue ob-
tained from tenALS patients and four non-ALS control patients was used
for miRNA analysis. iPSCs were reprogrammed from fibroblasts derived
from skin biopsies of subjects with or without ALS under Johns Hopkins
institutional review board protocols (NA_00021979: Skin Biopsies to
GenerateCell Lines for Study of Amyotrophic Lateral Sclerosis, approved
10/16/2008, andNA_00033726: Generation and Characterization of Cell
Lines for Amyotrophic Lateral Sclerosis, approved 1/19/2010). Consents
included the authorization to use DNA, fibroblasts, or cell lines derived
from fibroblasts for research purposes only.
Statistical and data analysis
Data arepresented asmeanSEM.All statistical testswere conductedusing
R’s Bioconductor toolkit, Microsoft Excel, or GraphPad Prism 6 software.
Array data were normalized by global LoessM in R studio as described pre-
viously (Risso et al., 2009). Adjusted p-values were calculated using the
Benjamini–Hochberg correction (Klipper-Aurbach et al., 1995).
Differentially expressed fromnontransgenic.To account for background
miRNA expression associated with the myc-IP, we performed TaqMan
miRNA microarrays on RNA from myc IP of both brainstem and spinal
cord of littermate controls not expressing tAgo2. We determined back-
ground cycle threshold (CT) cutoffs empirically for each individual
miRNA and used these data to eliminate any miRNA not significantly
enriched over background.
For a given sample, data were excluded for a miRNA if it failed to be
expressed at a significant level over the corresponding microarray data
from three myc-IP miRNA extractions from negative control mice
matched by tissue type. The criteria for differential expression were as
follows: (1) the miRNA must be expressed in at least two of three repli-
cates (three of four for Ago2); (2) themedian expression of the triplicates
for a given miRNA must be CT 35 (CT 37 for Ago2); and (3) the
highest CT of the triplicates for a given miRNA must be 2 CT  the
medianCTof the nontransgenics. Specifically, the number ofmiRNAs in
each cell type that were found to be expressed significantly over noise
were as follows: 257 (ChAT, brainstem), 295 (ChAT, spinal cord), 406
(Syn, brainstem), 417 (Syn, spinal cord), 325 (GFAP, brainstem), 295
(GFAP, spinal cord), 123 (Lyz2, brainstem), 56 (Lyz2, spinal cord), 484
(Ago2, brainstem), and 467 (Ago2, spinal cord).
Endogenous miRNA controls. To identify putative housekeeping
miRNAs, we used the following criteria. Using the LoessM-normalized
CTs, we subsetted formiRNAs with a low SD (1) among the triplicates.
The mean CT of the triplicates had to be 24 for all cell types. miR-24,
miR-30c, andmiR-191 were the top three miRNAs that met these criteria.
Pairwise comparisons. For miRNAs that met the criteria for being dif-
ferentially expressed from the nontransgenics, relative expression data
were generated for all pairwise comparisons between cell types in both
tissues. Significant changes in miRNA expression profiles were determined
byempiricalBayesgiven the lowsamplenumber, the largenumberof targets
(672 miRNAs), and the inability to assume normal distribution (Smyth,
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2004). Adjusted p-values were calculated using the Benjamini–Hochberg
correction (Klipper-Aurbach et al., 1995).
Heatmap.miRNAswere included in the heatmap illustration (see Fig.
1D) if a given miRNA was found to have significant differential expres-
sion (Log2FC	 2 and p 0.01) in at least one comparison.
Specificity index.We used the R Package pSI (Xu et al., 2014) to define
which miRNAs were enriched in each cell type compared with all others,
with minor adaptations to the input for use with qPCR microarrays.
MN-enriched miRNAs. The top six miRNAs enriched in MNs were
defined by the following criteria: (1) the geomean of the ChAT triplicates
from the arrays30 CT and differentially expressed from nontransgenic
for both tissues; (2) fold change 1.75 in all spinal cord comparisons;
and (3) adjusted p-value0.1 in ChAT versus Syn comparison in either
brainstem or spinal cord.
Comparison withMN-depletedmRNA.miRNA target predictions were
downloaded from mirDB (Wong and Wang, 2015) and targets with a
confidence	60 were extracted for each of the five MN-enriched miRNAs.
These targets were tested for overlap with mRNAs differentially trans-
lated between postnatal MN and postnatal spinal cord neurons (R. Ou-
wenga, A. Lake, A. Yoo, J. Dougherty, Washington University, personal
communication). These data are available on Gene Expession Omnibus
(accession number pending). Differentially translated genes were de-
fined as logFC	 1 and p 0.05 by negative binomial test implemented
in EdgeR. One-tailed Fisher’s exact test with Benjamini–Hochberg mul-
tiple testing correction was used to test for overlap. Pathway analysis was
performed using DAVID 6.8 (da Huang et al., 2009a, 2009b).
Results
Generation of cell-specific expression of GFP-myc-Ago2 in
CNS tissues
We adapted the miRAP method developed by He et al. (2012) to
express tAgo2 in specific cell populations relevant to ALS. Double-
transgenic mice carrying alleles of Cre recombinase under various
promoters and LSL-tAgo2 in the Rosa26 locus were generated (Fig.
1A). To target cell-type-specific expression of Cre recombinase,
and thus cell-type-specific expression of tAgo2, we used existing
Cre lines with the following promoters: Syn (Hilfiker et al., 1999),
ChAT (Rotolo et al., 2008), GFAP (Bajenaru et al., 2002), or Lyz2
(Clausen et al., 1999; Faust et al., 2000) targeting a pan-
neuronal-,MN-, astrocyte-, ormicroglia-containing cell popula-
tion, respectively.
We harvested brainstems and spinal cords from replicate adult
mice carrying both Cre recombinase and LSL-tAgo2 alleles (experi-
mental mice) or only LSL-tAgo2 (negative controls). Double-label
immunofluorescence histology using a cell-specific antibody and
an antibody against GFP indicated that tAgo2was expressed in the
desired cell types (data not shown). InChAT-Cre double-transgenic
mice, tAgo2 expressionwas restricted to theChAT brainstemmo-
tor nuclei and spinal MNs (Fig. 1B). After BCA normalization for
protein input,miRAPwas performedon these tissues using either
myc or Ago2 antibodies (Fig. 1C). The resulting miRNAs were
isolated and assayed via TaqManmiRNAmicroarrays v3.0 (AB
cards). On a global level, the miRNA expression profiles for CNS
cell types are distinct. After unsupervised 3D principal component
analysis (PCA), we found that miRNA expression profiles were suf-
ficient to cluster samples by their cell type of origin (Fig. 1E). Fur-
thermore, miRNA expression profiles from IP of tagged and
untagged Ago2 from each transgenic mouse clustered together in
PCA, indicating that the global miRNA expression in these mice is
comparable (Fig. 1E). Hierarchical heat maps also demonstrated
that these CNS cell types can be identified by their unique miRNA
expression profiles (Fig. 1D).
Because U6 snRNA, often used for miRNA normalization, is
not typically loaded into Ago2, miRAP studies must use endoge-
nousmiRNA controls for normalization of RT-qPCRdata. Using
this global miRNA array data, we identified miRNAs that are
consistently expressed across CNS cell types in both brainstem
and spinal cord: miR-24, miR-30c, and miR-191 (Fig. 1F). The use
of thesemiRNAs as endogenous controls for normalizingRT-qPCR
data will greatly aid in future studies of miRNAs in the CNS. Fur-
thermore, these results align well with previous reports identifying
putative housekeepingmiRNAs (Peltier and Latham, 2008).
Identification of MN-enriched and other CNS
cell-type-enriched miRNAs
To identifyMN-enrichedmiRNA expression, we used a heuristic
approach followed by the specificity index (pSI), an algorithm
designed to define the set of transcripts enriched in each cell popu-
lation compared with all others at a given permutation based statis-
tical threshold. We previously validated the performance of this
algorithm and its robustness to minor contamination in a given
population (Dougherty et al., 2010). Using the heuristic ap-
proach, we identified six miRNAs that were enriched in either
brainstemorspinalMNscomparedwithallotherneurons(1.75-fold,
adjusted p  0.1) and abundantly expressed (CT 30) with the
arrays. All six of these transcripts were also enriched in either
brainstemor spinal cordMNs comparedwith all other samples of
p  0.1 using the permuted pSI statistic. Using individual RT-
qPCR assays at a higher power (n 
 6), we confirmed the MN-
enrichment of five of the top six miRNAs (Fig. 2A) (miR-380-5p
could not be confirmed due to nonspecificity of TaqMan primers:
repeatedamplification inno-template control).miR-218-5p and its
lesser abundant 3p strand exhibited the strongest enrichment in
adult MNs compared with all other spinal neurons (Fig. 2A),
which had been demonstrated previously in embryonic MNs
(Amin et al., 2015; Thiebes et al., 2015). The MN enrichment of
miR-218 in adult mouse spinal cord was further confirmed by in
situ hybridization. miR-218 is detected predominantly in the
ChATMNs in the anterior horns of the spinal cord by in situ,
but not in other cell types (Fig. 2B). Because oligodendrocytes are
also abundant in the CNS, we performed miRAP independently
on LSL-tAgo2, Cnp1-Cre mice (Lappe-Siefke et al., 2003) and
performed individual RT-qPCR assays to verify that MN-
enriched miRNAs were not abundant in oligodendrocytes in the
spinal cord. All fiveMN-enrichedmiRNAs were significantly en-
riched in ChATMNs compared with Cnp1 oligodendrocytes
in the spinal cord (Fig. 2C). As expected, miR-338-3p, a miRNA
known to be enriched in oligodendrocytes, was 25-fold more
abundant in oligodendrocytes than MNs (Zhao et al., 2010; de
Faria et al., 2012) (Fig. 2D).
Because ALS is a disease characterized byMN loss, the focus of
this work was to use an in vivo approach that would be amenable
to definingMN-enrichedmiRNAs comparedwith other CNS cell
types. However, because dysregulation in glia also plays an im-
portant role in ALS and other disorders (Boille´e et al., 2006; Ya-
manaka et al., 2008; Ilieva et al., 2009), we have also analyzed our
data to define sets of miRNAs that were enriched in astrocytes,
microglia, and all other neurons. All comparisons made using
LoessM-normalized array data are included in Fig. 1-1 available
at https://doi.org/10.1523/JNEUROSCI.3582-16.2017.f1-1.
mRNA targets of MN-enriched miRNAs
To determine whether MN-enriched miRNAs might functionally
regulate MN translational profiles, we examined the ribosomal oc-
cupancy of the predicted targets of theMN-enrichedmiRNAs using
translating ribosome affinity purification (TRAP). Comparing the
ribosome-bound transcript levels between MNs (ChAT-TRAP
mouse line) with ribosome-bound transcripts from all spinal
Hoye et al. •Motor Neuron-Enriched miRNAs as Markers of ALS J. Neurosci., May 31, 2017 • 37(22):5574–5586 • 5577
neurons (Snap25-TRAPmouse line), we found a significant pre-
ponderance of targets of both mir-218-5p and mir-133a-3p
among those mRNAs relatively decreased in the MNs and in-
creased in all other neurons (Fig. 3A). For mir-218-5p, this is
consistent with prior work suggesting that mir-218 suppresses
mRNAs characteristic of interneurons in developing embryonic
MNs (Amin et al., 2015). Importantly, our work suggests miR-
218 retains its MN specificity in adults and may be essential in
maintaining MN identity distinct from other spinal neurons in
addition to interneurons. We were also able to identify a similar
role for mir-133a-3p, the predicted targets of which include
Foxp2 and Lhx5, which are both transcription factors known to
regulate the fate of non-MNs in the spinal cord (Dasen et al.,
2008; Pillai, 2007). Intriguingly, miR-133a has been studied ex-
Figure 1. Generation of cell-specific expression of GFP-myc-Ago2 and identification of CNS cell-type-enriched miRNA expression profiles. A, Mice were generated to express Cre recombinase
under cell-type-specific promoters. Cre recombinase drives expression of a taggedmiRNA-binding protein, Ago2, in the desired cell type. B, Spinal cord sections from transgenic mice were stained
for ChAT (red;MNs) andGFP (green). Scale bar, 50m.C, Schematic ofmiRAPdemonstrating selective expression of GFP-myc-taggedAgo2 inMNs,which allows for IP ofmyc to isolatemiRNAs from
only MNs or IP of Ago2 to isolate miRNA from all spinal cord cell types. D, Hierarchical heat map clustering demonstrating that spinal cord CNS cell types can be identified by their unique miRNA





 Syn/all neurons). Values are expressed as log2 fold change. E, 3D PCA illustrating that CNS cell types cluster according to their miRNA expression profiles. The replicates of each
spinal cord cell type clusterwith each othermore so thanwith any other cell type.miRNAexpression fromAgo2 IP fromone of each of these fourmice cluster, indicating that globalmiRNA signatures
are comparable. F, Putative endogenous miRNA controls for CNS cell types. Using global LoessM normalization of the miRNA microarray data, miR-191, miR-24, and miR-30c were found to be
expressed consistently across CNS cell types in both brainstem and spinal cord. For the CNS cell types analyzed here, thesemiRNAs could serve as controls for normalizingmiRNA RT-qPCR data. The
LoessM-normalized miRNA array data for CNS cell types in both brainstem and spinal cord and the miRNAs found to be enriched in these cell types can be found in Fig. 1-1 available at
https://doi.org/10.1523/JNEUROSCI.3582-16.2017.f1-1.
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tensively in the context of muscle (Chen et al., 2006), but this
work suggests that it may also function in the spinal cord to
reinforce MN identity. Because miRNAs repress mRNA transla-
tion, it is expected that targets of MN miRNAs would be more
highly expressed in non-MNs (Snap25). Using DAVID analysis,
we found that genes associated with transcription and transcrip-
tion regulation were represented significantly in the non-MN
(Snap25)-enriched genes that are regulated by MN miRNAs (Fig.
3B). ThemiR-218 (green) andmiR-133a (blue) targets associated
with transcription are labeled. These analyses suggest that MN-
enriched miRNAs play a functional role in defining postnatal
MN identity.
Depletion of MN-enrichedmiRNAs in spinal cord from ALS
rodent models and patients
To determine whether MN-enriched miRNAs are relevant for
MN disease, we characterized their expression in the spinal cords of
ALS rodent models and human ALS patient autopsies. In our con-
genic ALS mouse model [B6.Cg-Tg(SOD1G93A)1Gur/J] colony
(Wooley et al., 2005), disease onset typically occurs 130 d, as
marked by time to peak weight. We per-
formed RT-qPCR on SOD1G93A spinal
cord harvested at 56, 84, 105, 126, and
147 d, as well as at end stage (marked by
animal’s inability to right itself within
30 s). As was anticipated for a disease that
causes MN loss, there was a robust and
highly significant temporal depletion of the
MN-enriched miRNAs miR-218 and miR-
138 inSOD1G93A spinal cords beginning as
early as 126 d (Fig. 4A). This depletionwas
maximized in the end-stage ALS mouse
model spinal cord. Following a similar
trend, pan-neuronal enriched miRNAs
miR-382 and miR-672 were decreased,
butnot significantlydepleted, inALSmouse
model spinal cord, even at end stage (Fig.
4B). In ALS model rats, disease onset simi-
larly occurs between 120 and 140 d. Like
ALSmice,MN-enrichedmiRNAswere also
more significantly depleted than pan-
neuronal miRNAs in SOD1G93A rat spinal
cords (Fig. 4C). Finally, miR-218 was also
significantly depleted in ALS patient au-
topsy spinal cord compared with non-
neurodegenerative disease autopsy spinal
cord controls (Fig. 4D). Both ALS rodent
models and human patient autopsy spinal
cord tissue indicate a robust depletion of
MN-enriched miRNA expression, consis-
tent with MN loss throughout disease
progression. These data in ALS models
and human ALS validate our rigorously
defined list of MN-enriched miRNAs as
being relevant for MN disease. We hy-
pothesize that these miRNAs will inform
broadly on MN biology and MN disease.
miR-218 levels are maintained in
survivingMNs in ALS mice
Although miR-218 depletion in the ALS
rodent model and ALS patient autopsy
spinal cord tissue is likely due to MN loss,
it is possible that miR-218 is downregulated in ALS MNs. It was
shown recently that genetic ablation of miR-218 results in MN
degeneration (Amin et al., 2015), so it is conceivable that de-
creased miR-218 contributes to MN degeneration in adult MNs
in ALS. To test this hypothesis we used two orthogonal ap-
proaches: First, we performedmiRAP on LSL-tAgo2, ChAT-Cre,
SOD1G93A mice to probe miR-218 expression in ALS MNs and,
second, we examined miR-218 expression in ChAT MNs in
control and SOD1G93Amouse spinal cord tissue by in situ hybrid-
ization. In whole SOD1G93A mouse spinal cord tissue, miR-218
was not depleted significantly until 126 d. Therefore, we probed
miR-218 expression in ALS MNs at 70 and 140 d and found that
miR-218 levels were not significantly changed in the survivingMNs
from presymptomatic to symptomatic time points (Fig. 5A). To
confirm this finding, we performed miR-218 in situ hybridization
using spinal cord tissue from140dSOD1G93A and littermate control
mice.We found that themiR-218 fluorescence signals were also not
significantly different (Fig. 5B,C), but the number of ChATMNs
per unit area were, confirming that ChATMNs were lost in ALS
mouse model spinal cords (Fig. 5C,D). Together, these two ap-
Figure 2. Identification of MN-enriched miRNAs in CNS tissues. A, Individual RT-qPCR assays confirming the specificity of
MN-enriched miRNAs compared with all other spinal cord neurons. n
 6. Values are expressed as means. B, miR-218 (red) is
detected inChAT (green)MNs in theanteriorhornsof adultmouse spinal cordby in situhybridization. Scalebar, 50m.C,miRAP
of LSL-tAgo2, Cnp1-Cre mice followed by individual RT-qPCR assays indicates that MN-enriched miRNAs are significantly more
abundant in MNs than oligodendrocytes in the spinal cord. n
 5–6. D, The oligodendrocyte-enriched miRNA miR-338–3p is
more abundant in oligodendrocytes than MNs in the spinal cord, indicating that miRAP works in LSL-tAgo2, Cnp1-Cre mice. n

5–6.Values are expressedasmeanSEM.Relative expressionnormalized to ageometricmeanofmiR-30c,miR-24, andmiR-191
(A, C,D). Student’s unpaired, two-tailed t test with Bonferroni correction for multiple (five, A) or (six, C andD combined) compar-
isons. ****p 0.0001.
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Figure 4. MN-enrichedmiRNAs are depleted temporally in ALS rodentmodel and human patient spinal cord.A, TheMN-enrichedmiRNAsmiR-218 andmiR-138 are significantly depleted in ALS
mouse (SOD1 G93A)model spinal cord. This depletionoccurs temporally and ismaximizedat end stage.n
3–4.B, Pan-neuronal enrichedmiRNAsarenot significantly depleted inALSmousemodel
spinal cord, even at end stage. n
 3–4. C, MN-enrichedmiR-218 is significantly depleted in ALS ratmodel spinal cord andmore so than the pan-neuronalmiRNAsmiR-382 andmiR-672.n
 4–5.
D, miR-218 is significantly depleted in human ALS patient autopsy spinal cord compared with age-matched controls. n
 4–10. Values are expressed as mean SEM. *p 0.05, **p 0.01,
***p 0.001, ****p 0.0001, one-wayANOVAwithmultiple comparisons (Dunnett’s) (A), Student’s unpaired, two-tailed t test (B,D), and two-wayANOVA (C). Relative expression is normalized
to RNA input and endogenous miRNA control miR-24 (A, B) or U6 snRNA (C, D).
Figure 3. MN-enrichedmiRNAs repress non-motor neuron transcription-associatedmRNA expression.A, Forest plot indicating the odds ratio ofMN depletedmRNAs (Snap25 increasedmRNAs)
having target binding sites of MN-enriched miRNAs. B, Volcano plot indicating the Snap25-enriched mRNAs containing miR-218 (green) or miR-133a (blue) binding sites. The labeled mRNAs are
associated with transcription and transcription regulation. These terms were significantly represented ( p 
 0.022 and 0.033, respectively, Benjamini–Hochberg corrected) in the Snap25-
upregulated mRNAs containing MN-enriched miRNA-binding sites using DAVID analysis.
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proaches indicate thatmiR-218depletion inALS spinal cord tissue is
likely due toMN loss becausemiR-218 levels aremostlymaintained
within the survivingMNs.
miR-218 increases in ALSmodel CSF
To determine whether MN-enriched miRNAs may be a useful
marker of MN health, we examined MNmiRNAs in CSF, which
bathes the brain and spinal cord. We hypothesized that MN
miRNAs would be depleted in CSF during MN disease similar to
spinal cord tissue. We used ALS SOD1G93A rats (Howland et al.,
2002) for these CSF studies because of the larger volume of CSF
obtained from rats compared withmice. Surprisingly, miR-218 was
temporally increased in the CSF of ALS model rats compared with
nontransgenic littermate controls (Fig. 6A).Toensure that this effect
was not simply due tohSOD1overexpression (Chan et al., 1998),we
measured miR-218 levels in CSF from rats overexpressing WT
hSOD1 at 90 and 165 d. miR-218 CSF levels were not significantly
different in hSOD1WT rats compared with nontransgenics at either
time point (Fig. 6A). Furthermore, increased expression ofmiR-218
in ALS rat model CSF is not due to global increases in miRNA ex-
pression in CSF because the neuronal miRNAs miR-132 and miR-
124 were not significantly changed in rat SOD1G93A CSF compared
with nontransgenic controls (Fig. 6B). These data suggest that miR-
218 levels are increased in CSF duringMN disease.
Because miR-218 is highly enriched in MNs compared with
other CNS cell types, its increased levels in CSF during MN dis-
ease are potentially related to MN loss or dysfunction. Because
MN loss inALSmodel rats is due to expression ofmutant hSOD1,
we hypothesized that decreasing the levels of the toxic transgene
SOD1G93A would spare MNs and their function, potentially pre-
venting increasedmiR-218 levels in the CSF.We used ASOs against
SOD1 to specifically lower hSOD1 and prevent the loss of hindlimb
grip strength (Smith et al., 2006). We treated ALS SOD1G93A rats
with hSOD1 ASO or aCSF (the vehicle solution used for delivery of
drugs to the CNS). As predicted, hSOD1 mRNA was significantly
lowered (75%) in the lumbar spinal cord of these animals (as-
sessed 50 d after treatment; Fig. 7A) and hindlimb grip strength was
preserved (Fig. 7B), confirming a functional effect of reducing the
toxic SOD1 transgene. miR-218 CSF levels were not reduced in
scrambledASO-treated rats (Fig. 7C)but, strikingly,were reduced in
the hSOD1 ASO-treated group (Fig. 7D) compared with aCSF-
treated littermate controls. However, the CSF levels of neuronal
miR-132 and 124 were not affected by SOD1 ASO treatment, dem-
onstrating thatmiR-218CSF levels are selectively responsive toMN-
function-sparing therapy (Fig. 7E). Furthermore, hSOD1 mRNA
levels correlate well with miR-218 CSF levels, indicating that the
increased miR-218 CSF levels are directly responsive to MN-
function-sparing therapy and may be a relevant proxy for MN
health duringMNdisease (Fig. 7F). Finally, treatment of nontrans-
genic rats with aCSF and scrambled or hSOD1 ASO does not affect
miR-218CSF levels (Fig. 7G). Together, these data demonstrate that
MN-enriched miR-218 may serve as a drug-responsive marker of
MN disease in ALSmodel rats.
Figure 5. miR-218 levels are maintained in surviving MNs in ALS model mice. A, miR-218 levels in ALS spinal MNs are not significantly changed from presymptomatic (70 d) to symptomatic
(140 d) time points in ALSmodelmice. n
 5/time point.B, miR-218 fluorescent signal in ChAT spinalMNs is not changed significantly between littermate control and SOD1 G93A 140 dmice. n

46–49 ChAT MNs/group. C, Representative images of miR-218 in situ and ChAT staining in control and SOD1 G93A 140 d mouse model spinal cord. Scale bar, 50m. D, Quantification of 10
littermate control and 20 SOD1 G93A spinal cord sections. The number of ChAT spinal MNs per unit area is significantly different between littermate control and SOD1 G93A 140 d mice. Values are
expressed as mean SEM (A, B, D). ****p 0.0001. Student’s two-tailed, unpaired t test (A, B, D).
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Relationship betweenMN loss and
extracellular miR-218
It has been demonstrated previously
that tissue-enriched miRNAs are in-
creased in serum after injury to those tis-
sues (Corsten et al., 2010; Zhang et al.,
2010). Similarly, we found that a MN-
enriched miRNA, miR-218, is increased
in the CSF of ALS model rats, a MN dis-
ease. To determine whether miR-218 is
released extracellularly subsequent toMN
loss, we correlated miR-218 CSF levels to
the number of spinal MNs and miR-218
levels in spinal cord tissue of ALS model
rats. To mark MNs in the anterior horns
of the lumbar spinal cord, we used SMI-32
(which is also known as neurofilament
heavy). Overall, increased miR-218 CSF
levels are highly and significantly corre-
lated with loss of SMI-32MNs in spinal
cord tissue (Fig. 8A). Moreover, the num-
ber of SMI-32MNs and miR-218 levels
in the spinal cord are positively correlated,
suggesting miR-218 spinal cord levels can
be used as a proxy for total number of
MNs (Fig. 8B). Although increased miR-218 CSF levels are asso-
ciatedwithMN loss, becausemiR-218 can bemeasured readily in
the CSF of nontransgenic rats, there may be a physiological level
of miR-218 release outside of the context of MN disease.
Previous studies suggest that ALS MNs die by necrosis/
necroptosis, which is a form of cell death that involves leakage of
cellular components into the extracellular space (Re et al., 2014).
IncreasedmiR-218CSF levels due toMN losswould be consistent
with ALS MNs dying by necrosis and subsequently releasing
miR-218 and other cellular components. To further investigate
whether MN loss leads to miR-218 release, we used Hb9-GFP
primary mouse MNs. miR-218 is measureable in the media of
these cells, making them a good model with which to study miR-
218 release.We treated primaryMNswith sodiumarsenite for 4 h
and sampled the media repeatedly at 0, 2, and 4 h to probe the
release ofmiR-218 and its relation to cell death. Similar toALS rat
CSF, miR-218 was increased temporally in the media of Hb9-
GFP MNs treated with sodium arsenite and this increase corre-
lated well with LDH activity, a media marker of cell death (Fig.
9A,B). Therefore, it is likely that the extracellular release of miR-
218 during MN disease is at least partially attributed to MN loss.
Finally, miR-218 is also present in the media of human iPSC-
derived MNs and is released in response to injury/death (Fig.
9C,D). These data suggest that miR-218 release is related to MN
dysfunction and death and occurs in both animal and human
models of MN loss and disease.
Discussion
This study employed tools to assess in vivomiRNA expression in
a cell-type-specific manner to discriminate MN-enriched
miRNA expression in CNS tissues.We anticipate that this dataset
of MN-enriched miRNAs will facilitate broad insights into MN
disease mechanisms, risk factors, and genetics underlying MN
vulnerability. Our data also suggest that MN-enriched miRNAs
may act functionally in MNs to repress transcription factors im-
portant for non-MNs and thus help to define postnatalMN iden-
tity. By focusing on MN-enriched miRNA expression in models of
MN disease, we defined a MN-specific and drug-responsive
marker in ALS rodents. Finally, this work intersects with a grow-
ing field of extracellular release of miRNAs and its physiological
and pathological consequences.
In vivo cell-type-specific expression profiling techniques allow
high-throughput access to key disease-relevant cell types, yet pre-
serve physiological relevance compared with traditional ex vivo
methods such as fluorescence activated cell sorting (FACS) and
laser capture and microdissections (LCMs). This in vivo ap-
proach is particularly relevant for ALS. MNs have long processes
that would be difficult to maintain during tissue dissociation for
FACS and dissociation is particularly challenging from adult an-
imals, which are key to profile in models of neurodegenerative
disease. There is also the possibility that dissociation itself may
induce stress-related changes in the profile. Likewise, LCM is
lower throughput and overlapping processes from neighboring
cells may contaminate the MN sample (Kummari et al., 2015).
We adopted a comparative, systematic approach to define MN-
enriched miRNA expression relative to other CNS cell types. In-
clusion of a pan-neuronal line allowed us to define which
miRNAs distinguish MNs specifically from neurons in general,
whereas comparison with profiles containing microglia and as-
trocytes provided key controls and baseline data to facilitate fu-
ture analyses with understanding the molecular correlates of the
well known histological response of these cell types to disease
pathology. The ability to define in vivo, cell-type-enriched ex-
pression enables broad application of the concept of profiling the
cell type most affected by a particular disease to understand dis-
ease mechanism and identify markers.
Although this work focused on MN-enriched miRNAs in
MN disease, ALS and other neurodegenerative disease pro-
cesses are non-cell autonomous (Ilieva et al., 2009). Therefore,
we also definedmiRNAs enriched in astrocytes, microglia, and
all other neurons (Fig. 1-1 available at https://doi.org/
10.1523/JNEUROSCI.3582-16.2017.f1-1) and we expect that
this dataset will be broadly informative for ALS and other
neurological diseases. For example, there is a growing body of
work showing that gliosis and glial dysfunction may precede
neuronal loss in many neurodegenerative diseases (Hong et
Figure 6. Levels of MN-enriched miRNAs are increased in ALS rat model CSF. A, miR-218 expression is increased temporally in
ALS rat model CSF. n
 5–7/time point. The 115 d and 130 d time points included rats ranging from 112–119 d and 126–134 d,
respectively. End-stage rats ranged from 160–242 d; average
 192 30 d. In addition, increased miR-218 levels in ALS rat
model CSF are not due solely to hSOD1 overexpression. miR-218 CSF levels are not increased at either 90 or 165 d in hSOD1 WT
overexpressing rats. n
 2–5/time point.B, The neuronalmiRNAsmiR-132 andmiR-124 are not significantly increased in ALS rat
model CSF. Values are expressed as mean SEM. Relative expression normalized to a geometric mean of miR-103a-3p, miR-24,
and miR-191. *p 0.05, **p 0.01, Kruskal–Wallis with multiple comparisons (Dunn) (A) and one-way ANOVA with multiple
comparisons (Dunnett’s) (B).
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al., 2016; Clayton et al., 2017), so understanding dysregulation
of glial-enriched miRNAs may also lead to novel biomarkers
and therapies.
Furthermore, the dataset generated here could identify addi-
tional novel miRNAs involved in cell fate specification, particu-
larly those exhibiting enriched expression in a single CNS cell
type. For example, recent work indicates that miR-218 is en-
riched in MNs of other organisms (Kapsimali et al., 2007; Pun-
namoottil et al., 2015), may be important for MN differentiation
(Thiebes et al., 2015), and is indispensable for embryonic MNs
(Amin et al., 2015). Our work demonstrates thatmiR-218 retains
its specificity in adultMNs and also identifies otherMNmiRNAs
that may be equally important. By comparing the actively trans-
lated mRNAs in MNs with all other spinal neurons, we demon-
Figure7. hSOD1knockdown specifically and effectively preservesMN function andMN-enrichedmiRNAs are responsive to therapy.A, hSOD1mRNAknockdownafter treatmentwith hSOD1ASO.
There is an average 75% reduction in hSOD1 levels in the lumbar spinal cord of SOD1 G93A rats treatedwith SOD1 ASO comparedwith aCSF-treated controls. n
 7/group.B, Hindlimb grip strength
of aCSF, scrambled ASO, and hSOD1 ASO-treated SOD1 G93A rats at 80, 115, and 150 d. C, miR-218 CSF levels are not significantly different in aCSF- and scrambled ASO-treated SOD1 G93A littermates.
n
 8–10.D,miR-218 in CSF is reduced in rats treatedwith SOD1-loweringASO comparedwith aCSF-treated controls.n
 7/group. These aCSF vs scrambledASOand aCSF vs hSOD1ASO treatment
cohorts were tested at separate time points. E, The neuronal miRNAs miR-132 and miR-124 are not responsive to ALS therapy. n
 7/group. F, miR-218 CSF levels have a strong and significant
correlationwithhSOD1mRNAspinal cord levels.G,miR-218CSF levels are not changedafter treatmentwith aCSF, scrambled, or hSOD1ASO innontransgenic rats.n
5/group. Values are expressed
as mean SEM and are normalized to GAPDH (A) or a geometric mean of endogenous miRNA biological fluid controls, miR-103a, miR-24, and miR-191 (C–E, G). **p 0.01, ****p 0.0001,
Student’s unpaired, two-tailed t test (A, C, D, E), one-way ANOVA (G), two-way ANOVA (B), linear regression analysis (F ).
Figure 8. Increased miR-218 CSF levels are correlated with number of remaining SMI-32 spinal MNs in ALS model rats. A, Number of SMI-32MNs in the lumbar spinal cord of ALS rats is
negatively andhighly correlatedwith their correspondingmiR-218CSF levels.B, Number of SMI-32MNs is positively andhighly correlatedwith correspondingmiR-218 levels in lumbar spinal cord
tissue. Linear regression analysis was used.
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strated that mRNAs containing binding sites for MN-enriched
miRNAs appear relatively repressed in the MNs. Because mRNA
and miRNA profiling was performed postnatally, these data sug-
gest that MN-enriched miRNAs continue to define MN identity
after development. In the future, it would be interesting to inves-
tigate how the downregulation of individual targets of MN-
enriched miRNAs maintains MN identity. Moreover, this same
approach can be applied tomiRNAs enriched in glial cell types as
well as miRNAs that are dysregulated in disease.
Our data also demonstrate that miR-218 is a marker of MN
loss and/or injury in ALS rat model CSF. Mouse miR-218
exists at two different genomic loci within the introns of SLIT2
and SLIT3 (miR-218-1, chr5: 48223942–48224051; miR-218-2,
chr11:35616816–35616925). Recently, miR-218 was shown to be
MN-enriched in mouse embryos and to be critical for MN func-
tion. Genetic deletion of both miR-218 loci in mice resulted in
embryonic inability to form functional neuromuscular junctions
and, ultimately, MN degeneration (Amin et al., 2015). Although
the loss of miR-218 developmentally causes MN degeneration,
we found that miR-218 spinal cord levels are depleted due toMN
loss, not downregulation, and mir-218 levels are maintained in
theMNs that survive in ALS (Fig. 5A–D). These data indicate that
miR-218 loss from spinal cord tissue is likely subsequent to
MN loss in ALS and thus may not be a cause of MN degener-
ation in ALS rodent models. However, it remains possible that
miR-218 could be downregulated acutely in each MN shortly
before death. Future studies involving in vitro cultures could
be used to monitor miR-218 levels dynamically in individual
ALS MNs antecedent to cell death. Regardless, our work cor-
roborates previous studies demonstrating the MN specificity
of miR-218, highlights the importance of miR-218 in adults,
and clarifies its relation to MN health and disease in ALS
models.
Currently, the mechanism underlying increased miR-218 in
ALS rat CSF is unknown. Our data are consistent with miR-218
being released extracellularly subsequent toMN loss (Figs. 8A, 9).
However, it is also possible that some release of miR-218 into the
CSFmay reflect an additional active response operating indepen-
dently ofMN loss because somemiR-218 is released into the CSF
before significant MN loss in ALS model rats (Fig. 8A). Although
clearance of proteins and other molecules into CSF can result from
normalphysiological processes, there is also increasing evidence that
release into theCSFcanbepathological aswell (Aluise et al., 2008; Su
et al., 2014). Future studies will help to delineate whether the in-
creased levels ofmiR-218 inALS ratCSF is solely due toMNloss and
subsequent clearance or to an active signal or homeostatic attempt
from diseasedMNs. Understanding whether miR-218 is also changed
in spinalmuscular atrophy, spinal cord injury, or otherMNdiseases
may also provide insights into the miR-218 CSF signal.
Despite many efforts, there are a limited number of reliable
biomarkers for ALS. One of the most promising biomarkers thus
far is neurofilament, amarker of neuroaxonal degeneration. Both
Figure 9. ExtracellularmiR-218 levels are increased subsequent toMN injury or death.A, miR-218 levels and LDH levels (shown as percentage cell toxicity) are temporally increased in themedia
of primary Hb9-GFP MNs treated with 1 mM sodium arsenite. n
 2/group. B, miR-218media levels are strongly correlated with LDH activity, a marker of cell death. n
 2/group with 3 technical
replicates per n. C, miR-218 is increased in the media of iPSC-derived MNs after puromycin treatment. n
 3. D, LDH activity (shown as percentage cell toxicity) is increased after puromycin
treatment. n
 3with 3 technical replicates per n. Values are expressed atmean SEMand are normalized tomedia volume (A, C). *p 0.05, **p 0.01, linear regression analysis (B), Student’s
unpaired, two-tailed t test (C, D).
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phosphorylated neurofilament heavy and neurofilament light
have been shown to be increased in CSF and serum of ALS pa-
tients comparedwith neurological disease controls (Rosengren et
al., 1996; Lu et al., 2015; Oeckl et al., 2016). Furthermore, neuro-
filament light is a good prognostic marker for ALS; higher CSF
levels are associated with shorter survival (Weydt et al., 2016;
Gaiani et al., 2017). In addition, repeat expansions in C9orf72
(C9) are attributed to	40% of ALS cases and dipeptide repeat
proteins (DPRs) produced from RAN translation of the repeats
can bemeasured in the CSF of C9ALS patients (Su et al., 2014).
It was demonstrated recently that these DPRs can serve as phar-
macodynamic biomarkers for C9 ALS patients (Gendron et al.,
2017).However, none of thesemarkers has been shown to change
longitudinally within individual patients as disease progresses.
We are optimistic that miR-218 could be used as a marker of
human ALS. However, at the present time using available meth-
ods, miR-218, although quantifiable in some samples, is below
the limit of detection in others and thus a valid comparison be-
tween ALS and controls is not yet achievable. Despite these lim-
itations, we remain enthusiastic that miR-218 will be measured
reliably in human CSF. In ALS model rats, miR-218 CSF levels
correlate well with the number of remaining spinal MNs, do not
appear to reach a plateau, and are responsive to MN-sparing
therapy. If miR-218 levels could be detected in humans, then CSF
miR-218 could be used to assess a drug’s ability to affect MNs,
thus potentially selecting amore promising candidate for a longer
trial. Furthermore, becausemiR-218 is increased temporally dur-
ing ALS rat model disease progression, longitudinal assessment
of miR-218 in clinical trials could indicate whether MN loss is
ongoing or if it has been stabilized by MN-sparing therapy.
Presently, miR-218 is measureable in the media of human
iPSC-derivedMNs (Fig. 9C). There has been an increased interest
in using iPSC models to generate preclinical data, especially for
ALS (Answer ALS, clinical trial NCT02574390). Themedia levels
of miR-218 may be a useful proxy for MN health in these studies
as well because RNA can be quantified from100l of medium.
Furthermore, because of theMN specificity of miR-218, this may
allow for monitoring of MN toxicity specifically when cultures
contain a variety of cell types.
This study has identified a MN-specific, drug-responsive
marker of an ALS rodent model of MN disease. Our approach
highlights a pipeline for hypothesis-driven development of spe-
cific miRNA markers of particular cell types and a means of pre-
dicting their functionality on mRNA expression in relevant cell
types. Although miR-218 needs further validation, especially in
human ALS CSF, it has the potential to become a MN-specific,
drug-responsivemarker in humans, with important implications
for the design and assessment of efficacy ofMNdisease therapies.
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